About Dr. Chukwunonso Nwabufo
Live. Powerful. Impactful
Dr. Chukwunonso Nwabufo is a Postdoctoral Scholar in the Department of Bioengineering, School of Medicine and College of Engineering, University of Washington, where he is developing novel microdevices for precision medicine applications. Dr. Nwabufo is the founder and CEO of OneDrug Inc., an innovative medical technology startup that is developing smart point-of-care technologies to advance the clinical implementation of precision medicine across the globe. He is a multiple award-winning translational pharmacologist with over eight years of experience in drug development across academia and the pharmaceutical industry. Dr. Nwabufo contributed to the development of Remdesivir and Lenacapavir, approved for the treatment of COVID-19 and HIV, respectively, during his tenure at Gilead Sciences. He also contributed to the development of novel compounds under basic science research for the treatment and/or diagnosis of Parkinson’s disease during his MSc program.
Dr. Nwabufo’s doctoral research work was focused on deploying pharmacological strategies to improve the clinical efficacy and safety profile of promising COVID-19 drugs. He has received numerous prestigious awards, including the Canadian Institutes of Health Research Canada Graduate Scholarship Doctoral Award, Canadian Institutes of Health Research Canada Graduate Scholarship – Michael Smith Foreign Study Supplements Award, Emerging Academic Scholars Award, Pfizer Canada Fellowship, Top 25 Canadian Immigrant for Healthcare Innovation, and 2024 Canadian CEO of the Year Award for Medical Technology Development. In general, he has received more than 35 international and national awards and recognitions with over $400,000 in funding due to academic, research, and leadership accomplishments. Dr. Nwabufo has authored 19 peer-reviewed scientific papers and 11 industry-standard peer-reviewed reports in support of drug development programs.
Dr. Nwabufo serves as an editorial board member of Drug Metabolism Reviews and Journal of Applied Bioanalysis. He has served as a Track Leader and Abstract Screener for the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Conference, and as Past Chair, Chair, and Vice Chair of the AAPS Pharmacokinetics, Pharmacodynamics, and Drug Metabolism Community. In addition, he contributes to the advancement of clinical pharmacology education and mentorship as a member of the Student, Trainee, and Early-Stage Professional Committee of the American College of Clinical Pharmacology.
